VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsEarningsCompareWatchlistInsider
VRPXVirpax Pharmaceuticals, Inc.$0.0001$425
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksVRPXEarnings History

VRPX logoVirpax Pharmaceuticals, Inc. (VRPX) Earnings History

Net Loss

7 years of earnings data (2018–2024) · Currently unprofitable on a TTM basis

TTM Net Income
-$12M
● Net Loss
TTM EPS (Diluted)
$-2.84
Per share, diluted
YoY EPS Growth
-446.7%
Declining
Net Margin
N/A
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating MarginN/A
Gross MarginN/A
Return on Equity-2364.8%
Return on Assets-215.8%
Record Annual Net Income-$3MFY2018
Record Quarterly EPS$-0.13Q1 2020
Consecutive Profitable Years0years
Q4 2024
Net Income-$3M
EPS (Diluted)$-0.80
YoY Growth-446.7%Declining
QoQ Growth-69.0%Declining

Loading earnings history...

Virpax Pharmaceuticals, Inc. (VRPX) Earnings Overview

As of May 30, 2026, Virpax Pharmaceuticals, Inc. (VRPX) reported trailing twelve-month net income of -$12M, reflecting -446.7% year-over-year growth. The company earned $-2.84 per diluted share over the past four quarters.

Looking at the long-term picture, VRPX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2018.

Virpax Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including NKTR (-$158M net income, -297.1% margin), PCRX ($9M net income, 1.0% margin), PRAX (-$327M net income), VRPX has comparable earnings metrics. Compare VRPX vs NKTR →

VRPX Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
VRPX logoVRPXCurrent
-$12M$-2.84--2364.8%-446.7%—
NKTR logoNKTR
-$158M$-6.39-297.1%-217.9%-12.1%
PCRX logoPCRX
$9M$0.231.0%1.0%+107.4%
PRAX logoPRAX
-$327M$-11.31--45.8%-32.0%
ABBV logoABBV
$4.2B$2.386.9%6214.7%-0.8%
PFE logoPFE
$7.5B$1.3112.4%8.9%-3.5%
Best in group
Lowest in group

VRPX Historical Earnings Data (2018–2024)

7 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2024-$12M+20.6%-$12M$-70.91--
2023-$15M+29.2%-$16M$-12.97--
2022-$21M-76.6%-$22M$-18.32--
2021-$12M-170.7%-$12M$-10.37--
2020-$4M-30.8%-$4M$-9.07--
2019-$3M-29.9%-$3M$-6.58--
2018-$3M--$3M$-0.53--

Download Data

Export VRPX earnings history in CSV or JSON format

Free sign-in required to download data

What if you invested $1,000 in VRPX back in 2018?

Total return with dividends reinvested · 8+ years of data

Calculate Returns

How much would $100/month in VRPX be worth today?

Dollar cost averaging vs lump sum · see how regular investing compounds over time

Run the Numbers

Is VRPX Undervalued Right Now?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

VRPX vs DBVT — which is the better buy?

Side-by-side revenue, margins, P/E and 10-year returns vs DBV Technologies S.A..

Compare Now

VRPX — Frequently Asked Questions

Quick answers to the most common questions about buying VRPX stock.

What is VRPX earnings per share (EPS)?

VRPX trailing twelve-month (TTM) diluted EPS is $-2.84, reflecting -446.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2024 is available in the table on this page.

What is Virpax Pharmaceuticals, Inc.'s net income?

Virpax Pharmaceuticals, Inc. (VRPX) trailing twelve-month net income is $-12M as of 2024. Earnings declined -446.7% year-over-year.

Is VRPX profitable?

VRPX is not currently profitable on a TTM basis, reporting a net loss of $-12M. Net margin is N/A. Investors should monitor for a return to profitability.

What is VRPX's earnings growth rate?

VRPX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2024.

What are VRPX's profit margins?

Virpax Pharmaceuticals, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -2364.8%.

Is VRPX growing earnings?

VRPX earnings are declining — EPS fell -446.7% year-over-year. TTM net income dropped to $-12M. This contrasts with the 5-year CAGR of N/A.

What was VRPX's best earnings year?

Virpax Pharmaceuticals, Inc.'s highest annual net income on record is $-3M, achieved in fiscal year 2018. Earnings history on this page spans 2018 to 2024 and includes all annual and quarterly figures.

What were VRPX's earnings last quarter?

VRPX's most recent reported quarter was Q4 2024. Net income was $-3M with diluted EPS of $-0.80. For a full breakdown of all quarters, see the quarterly earnings table on this page.

VRPX Earnings Over Time (2018–2024)

Net income & EPS — annual and quarterly view